PRNewsWire
16 Jul 2026, 23:52 UTC · 13w ago
Verdict
Headline takes no side. We score CELC −0.80 across three claims — strongly bearish.
−0.80strongly bearish
More negative than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Celcuity's commercial launch of Revtorpyk is scheduled for late Q3 2026, which is later than analyst expectations.
More negative than 94% of claims this week
Celcuity Inc. received FDA approval for its breast cancer therapy, Revtorpyk.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 88% of claims this week
Pomerantz LLP is investigating Celcuity for potential securities fraud or unlawful business practices following the launch timeline announcement.
More negative than 84% of claims this week
Which stocks this story touches
More negative than 85% of ticker scores this week
Company is facing a securities fraud investigation and a stock price drop due to a delayed product launch timeline.
More negative than 80% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 74% of ticker scores this week
The company is the subject of an investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1h ago
—
No price for CELC right now — the quote feed didn't answer.
CELC chart →
